https://www.appliedxl.com/news/neuregen-nrg-103-glioma-trial-nct07710690 Biopharma News en 2026-07-17T16:04:59.422Z Neuregen opens Phase 1 gene therapy trial for recurrent high-grade glioma https://www.appliedxl.com/news/stemline-men2312-breast-cancer-delay-nct06638307 Biopharma News en 2026-07-17T15:55:42.994Z Stemline's MEN2312 breast cancer trial timeline slips 16 months https://www.appliedxl.com/news/hengrui-hrs-7525-prostate-cancer-trial-nct07711184 Biopharma News en 2026-07-17T15:55:34.486Z Jiangsu HengRui registers first-in-human trial of oral prostate cancer drug HRS-7525 https://www.appliedxl.com/news/jiangsu-aidea-acc017-hiv-trial-nct07711223 Biopharma News en 2026-07-17T15:55:24.479Z Jiangsu Aidea tests oral ACC017 against dolutegravir as first-line HIV therapy https://www.appliedxl.com/news/inventisbio-d-2570-ulcerative-colitis-enrollment-nct07035041 Biopharma News en 2026-07-17T15:55:06.715Z InventisBio closes enrollment in Phase 2 oral D-2570 ulcerative colitis trial https://www.appliedxl.com/news/astrazeneca-azd1390-brain-cancer-enrollment-nct03423628 Biopharma News en 2026-07-17T15:55:06.586Z AstraZeneca trims AZD1390 brain-cancer trial to 159 patients as it nears its end https://www.appliedxl.com/news/newish-nwrd09-cervical-hsil-trial-nct07712692 Biopharma News en 2026-07-17T15:54:59.153Z Newish Biotech registers second HPV-16 cervical HSIL vaccine trial https://www.appliedxl.com/news/fujian-shengdi-hrs5580-ponv-trial-nct07709897 Biopharma News en 2026-07-17T15:54:55.697Z Fujian Shengdi advances HRS5580 to second Phase 2 PONV trial with Palonosetron https://www.appliedxl.com/news/sinotau-lutetium-177-oxodotreotide-neuroendocrine-nct06398444 Biopharma News en 2026-07-17T15:45:39.660Z Sinotau's Lutetium-177 trial in neuroendocrine tumors resumes recruiting https://www.appliedxl.com/news/sinotau-lu-177-oxodotreotide-neuroendocrine-nct06398444 Biopharma News en 2026-07-17T15:45:36.838Z Sinotau widens China trial of Lu-177 oxodotreotide as enrollment target rises to 85 https://www.appliedxl.com/news/astrazeneca-saruparib-prostate-cancer-trial-nct07711002 Biopharma News en 2026-07-17T15:45:13.540Z AstraZeneca opens third Phase 3 saruparib trial in prostate cancer https://www.appliedxl.com/news/immunogenesis-imgs-001-solid-tumors-timing-nct06014502 Biopharma News en 2026-07-17T15:45:08.520Z ImmunoGenesis pushes IMGS-001 tumor-trial readout a year to December 2027 https://www.appliedxl.com/news/sumgen-sanritatug-itp-trial-nct07710248 Biopharma News en 2026-07-17T15:45:04.897Z Hangzhou Sumgen starts Phase 2 CD38 trial for ITP, joining Takeda's Mezagitamab https://www.appliedxl.com/news/e-nitiate-qy201-vitiligo-phase2-nct07712523 Biopharma News en 2026-07-17T15:45:00.984Z E-nitiate starts Phase 2 trial of oral QY201 in non-segmental vitiligo https://www.appliedxl.com/news/newish-nwrd09-hpv16-trial-nct07710703 Biopharma News en 2026-07-17T15:44:54.745Z Newish Biotech starts randomized trial testing if NWRD09 clears persistent HPV16 https://www.appliedxl.com/news/bio-thera-bat3306-nsclc-enrollment-nct07180862 Biopharma News en 2026-07-17T15:40:01.302Z Bio-Thera raises BAT3306 biosimilar trial enrollment to 160 in NSCLC https://www.appliedxl.com/news/adc-zynlonta-lotis-7-lymphoma-nct04970901 Biopharma News en 2026-07-17T15:37:39.925Z ADC Therapeutics' Zynlonta-glofitamab combo posts 89.8% response rate in LOTIS-7 https://www.appliedxl.com/news/hengrui-shr-a1811-biliary-cancer-readout-nct06413745-89f8f0 Biopharma News en 2026-07-17T15:37:36.483Z Hengrui's SHR-A1811 biliary cancer trial pushes readout to end of 2026 https://www.appliedxl.com/news/hengrui-shr-a1811-biliary-cancer-readout-nct06413745 Biopharma News en 2026-07-17T15:37:36.265Z Hengrui's HER2 ADC SHR-A1811 stays on track in biliary cancer, enrollment trimmed to 59 https://www.appliedxl.com/news/abbisko-absk043-nsclc-phase2-nct07710612 Biopharma News en 2026-07-17T15:37:14.799Z Abbisko starts Phase 2 test of ABSK043 plus AstraZeneca's osimertinib in NSCLC https://www.appliedxl.com/news/jiangsu-aidea-acc017-hiv-resistance-nct07711210 Biopharma News en 2026-07-17T15:37:14.272Z Jiangsu Aidea tests ACC017 in HIV patients already resistant to NNRTIs https://www.appliedxl.com/news/shanghai-raas-sr604-factor-vii-deficiency-nct07711158 Biopharma News en 2026-07-17T15:35:53.967Z Shanghai RAAS opens a second Phase 2 test of SR604 in Factor VII deficiency https://www.appliedxl.com/news/suncadia-hrs-1780-ckd-enrollment-nct07419828 Biopharma News en 2026-07-17T15:35:41.956Z Suncadia triples target enrollment for HRS-1780 kidney-disease trial to 5,386 https://www.appliedxl.com/news/kelun-kl0011034-chronic-pain-ddi-trial-nct07710560 Biopharma News en 2026-07-17T15:35:39.301Z Kelun tests whether KL0011034 interacts with the anesthetic alfentanil https://www.appliedxl.com/news/lembas-edge-prediabetes-trial-nct07711288 Biopharma News en 2026-07-17T15:35:35.339Z Lembas registers a 35-person dietary-supplement trial for prediabetes https://www.appliedxl.com/news/vigonvita-vv261-phase1-china-nct07710326 Biopharma News en 2026-07-17T15:35:01.336Z Vigonvita Life Sciences plans multiple-dose Phase 1 tablet trial for VV261 https://www.appliedxl.com/news/excyte-yk012-lymphoma-timing-nct06565689 Biopharma News en 2026-07-17T15:34:58.498Z Excyte pushes YK012 lymphoma trial completion date back 18 months to 2028 https://www.appliedxl.com/news/asieris-hexaminolevulinate-photodynamic-therapy-hal-pdt-nct04484415 Biopharma News en 2026-07-17T15:55:23.061Z Asieris's HAL-PDT hits 57.5% CIN2 regression vs 30.6% for placebo https://www.appliedxl.com/news/inventisbio-d-1553-solid-tumor-timing-nct05379946 Biopharma News en 2026-07-17T15:27:59.010Z InventisBio's D-1553 trial pushes completion date out more than two years https://www.appliedxl.com/news/dizal-birelentinib-dlbcl-trial-nct07712588 Biopharma News en 2026-07-17T15:26:39.724Z Dizal registers Phase 2/3 trial pairing birelentinib with R-CHOP in frontline DLBCL https://www.appliedxl.com/news/hengrui-herombopag-liver-disease-thrombocytopenia-nct06507436 Biopharma News en 2026-07-17T15:26:39.216Z HengRui's herombopag Phase 3 closes enrollment, pushes readout to Dec 2026 https://www.appliedxl.com/news/hengrui-herombopag-thrombocytopenia-timing-nct06507436 Biopharma News en 2026-07-17T15:26:36.811Z HengRui pushes Herombopag surgery-readiness readout to December 2026 https://www.appliedxl.com/news/hengrui-herombopag-thrombocytopenia-readout-nct06507436 Biopharma News en 2026-07-17T15:26:36.289Z HengRui's herombopag trial closes enrollment at 127, eyes Dec. 2026 readout https://www.appliedxl.com/news/adc-zynlonta-lymphoma-timing-nct04970901 Biopharma News en 2026-07-17T15:26:35.949Z ADC Therapeutics' Zynlonta combo trial pushes primary readout to March 2027 https://www.appliedxl.com/news/fujian-mindong-rupatifen-allergic-rhinitis-nct07711262 Biopharma News en 2026-07-17T15:26:35.334Z Fujian Mindong opens Phase 3 test of dual H1/PAF blocker rupatifen in China https://www.appliedxl.com/news/newish-nwrd09-hpv16-nct07710664 Biopharma News en 2026-07-17T15:25:32.929Z Newish Biotech starts third NWRD09 trial, this time in anal HPV16 https://www.appliedxl.com/news/merck-bomedemstat-essential-thrombocythemia-2026-nct06456346 Biopharma News en 2026-07-17T15:25:30.286Z Merck closes enrollment in Phase 3 bomedemstat trial for essential thrombocythemia https://www.appliedxl.com/news/beijing-pins-hypoglossal-osa-trial-nct07711678 Biopharma News en 2026-07-17T15:25:01.353Z Beijing Pins Medical starts a 10-patient trial of its hypoglossal implant for OSA https://www.appliedxl.com/news/novartis-tulmimetostat-2026-enrollment-nct04104776 Biopharma News en 2026-07-17T15:17:05.666Z Novartis widens tulmimetostat trial to 300 as EZH2 field stays thin https://www.appliedxl.com/news/fujian-shengdi-ribupatide-osteoarthritis-obesity-nct07709910 Biopharma News en 2026-07-17T15:17:00.225Z Fujian Shengdi tests GLP-1/GIP drug on knee pain and weight together https://www.appliedxl.com/news/inflammasome-k8-kamuvudine-8-2026-readout-nct06164587 Biopharma News en 2026-07-17T13:14:52.204Z Inflammasome's K8 slows geographic atrophy 54% in small Phase 2 study https://www.appliedxl.com/news/cyb004-generalized-anxiety-disorder-gad-readout-2026-nct06051721 Biopharma News en 2026-07-17T13:05:49.419Z Helus Pharma's HLP004 anxiety data arrive via promotional release, not a trial disclosure https://www.appliedxl.com/news/medifast-optimal-weight-5-1-plan-readout-nct02835092 Biopharma News en 2026-07-17T12:46:29.255Z Medifast repackages a decade-old coaching trial to launch its Trilivy brand https://www.appliedxl.com/news/gcc-car-t-colorectal-cancer-phase1 Biopharma News en 2026-07-17T19:24:53.314Z GCC-targeted CAR-T shows 33% response rate in heavily pretreated colorectal cancer https://www.appliedxl.com/news/serum-biomarker-nsclc-immunotherapy Biopharma News en 2026-07-17T19:44:50.402Z Serum three-protein score predicts immunotherapy response in NSCLC https://www.appliedxl.com/news/dexmedetomidine-flurbiprofen-thyroidectomy-sleep Biopharma News en 2026-07-17T19:44:37.110Z Opioid-free analgesia preserves melatonin, sleep after thyroidectomy in trial https://www.appliedxl.com/news/hengrui-ivarmacitinib-hepatic-impairment-pk-nct04293029 Biopharma News en 2026-07-17T20:05:28.362Z Hepatic impairment leaves ivarmacitinib exposure largely unchanged, study finds https://www.appliedxl.com/news/btk-inhibitor-venetoclax-mantle-cell-lymphoma Biopharma News en 2026-07-17T20:25:10.300Z BTK inhibitor plus venetoclax lengthens survival in TP53-mutated mantle cell lymphoma https://www.appliedxl.com/news/iberdomide-relapsed-or-refractory-multiple-myeloma-rrmm-fda-decision Biopharma News en 2026-07-17T00:06:14.164Z BMS's iberdomide faces Aug. 17 FDA decision on an MRD-based myeloma filing https://www.appliedxl.com/news/e-nitiate-qy201-atopic-dermatitis-phase2-nct07712536 Biopharma News en 2026-07-17T15:25:36.772Z E-nitiate completes Phase 2 QY201 pharmacokinetic study in teen eczema https://www.appliedxl.com/news/lilly-orforglipron-bioequivalence-obesity-nct06440980 Biopharma News en 2026-07-17T15:47:09.379Z Lilly's orforglipron capsule matches tablet exposure in bioequivalence study https://www.appliedxl.com/news/newsoara-hpp737-psoriasis-phase3-nct07712705 Biopharma News en 2026-07-17T15:54:52.948Z Newsoara completes 515-patient Phase 3 of oral psoriasis drug HPP737 in China https://www.appliedxl.com/news/newsoara-hpp737-psoriasis-phase3-nct07712731 Biopharma News en 2026-07-17T15:36:29.406Z Newsoara completes Phase 3 test of oral PDE4 drug HPP737 in psoriasis https://www.appliedxl.com/news/takeda-zasocitinib-tak-279-2026-readout-nct06088043 Biopharma News en 2026-07-16T22:15:43.712Z Zasocitinib clears scalp, nail and palm psoriasis at high rates in Takeda Phase 3 data https://www.appliedxl.com/news/takeda-zasocitinib-tak-279-2026-readout-nct06108544 Biopharma News en 2026-07-16T22:15:19.792Z Takeda's zasocitinib clears hard-to-treat psoriasis sites in Phase 3 follow-up https://www.appliedxl.com/news/huilun-hl-1186-postoperative-pain-trial-nct07709598 Biopharma News en 2026-07-16T15:45:28.543Z Shanghai Huilun opens second Phase 2/3 HL-1186 pain trial against oxycodone https://www.appliedxl.com/news/hengrui-hrs-6209-breast-cancer-delay-nct06555068 Biopharma News en 2026-07-16T15:36:02.747Z HengRui's HRS-6209 breast cancer trial pushes completion out two years https://www.appliedxl.com/news/takeda-elritercept-mds-enrollment-nct07319845 Biopharma News en 2026-07-16T15:35:45.491Z Takeda expands Japan trial of elritercept for lower-risk MDS anemia https://www.appliedxl.com/news/boehringer-bi-3034701-obesity-pk-study-nct07708493 Biopharma News en 2026-07-16T15:35:15.492Z Boehringer registers mass-balance study of obesity drug BI 3034701 https://www.appliedxl.com/news/innovent-ibi3035-phase1-recruiting-nct07591519 Biopharma News en 2026-07-16T15:35:09.142Z Innovent starts dosing IBI3035 in first-in-human trial against Novo, Lilly insulins https://www.appliedxl.com/news/fujian-akeylink-gst-hg131-hepatitis-b-phase2-nct07709520 Biopharma News en 2026-07-16T15:35:08.387Z Fujian Akeylink starts Phase 2 test of oral GST-HG131/141 in hepatitis B https://www.appliedxl.com/news/suncadia-hrs-2129-gout-trial-nct07706777 Biopharma News en 2026-07-16T15:34:59.972Z Suncadia registers Phase 2 trial testing HRS-2129 against gout flare pain https://www.appliedxl.com/news/radicle-science-menopause-fatigue-trial-nct07572578 Biopharma News en 2026-07-16T15:34:58.297Z Radicle Science's menopause fatigue trial moves to Active, not recruiting https://www.appliedxl.com/news/abbvie-emrelis-lung-cancer-delay-nct04928846 Biopharma News en 2026-07-16T15:25:20.090Z AbbVie pushes confirmatory lung cancer trial for Emrelis nine months https://www.appliedxl.com/news/lilly-baricitinib-sjia-enrollment-complete-nct04088396 Biopharma News en 2026-07-16T15:16:38.632Z Lilly's pediatric baricitinib trial closes enrollment after six delays https://www.appliedxl.com/news/daewoong-bersiporocin-ipf-readout-nct05389215 Biopharma News en 2026-07-16T15:16:10.005Z Daewoong's IPF trial closes enrollment as its 2026-10-13 readout nears https://www.appliedxl.com/news/suncadia-hrs-1780-hypertension-trial-nct07708441 Biopharma News en 2026-07-16T15:16:03.470Z Suncadia registers Phase 2/3 test of MRA HRS-1780 in resistant hypertension https://www.appliedxl.com/news/medilink-yl201-esophageal-cancer-phase3-nct07487896 Biopharma News en 2026-07-16T15:16:02.406Z MediLink's YL201 enters Phase 3 recruiting against chemo in esophageal cancer https://www.appliedxl.com/news/sichuan-baili-si-b036-phase1-enrollment-nct07678970 Biopharma News en 2026-07-16T15:15:19.150Z Sichuan Baili trims early Phase 1 trial of SI-B036 to 10 patients before dosing starts https://www.appliedxl.com/news/nexcella-nxc-201-al-amyloidosis-phase3-nct07709715 Biopharma News en 2026-07-16T15:14:59.060Z Nexcella moves NXC-201 into head-to-head Phase 3 test against daratumumab https://www.appliedxl.com/news/baili-bl-b01d1-esophageal-cancer-trial-nct07554456 Biopharma News en 2026-07-16T15:08:21.650Z Baili's BL-B01D1 opens enrollment in first-line esophageal cancer trial https://www.appliedxl.com/news/chia-tai-tianqing-tq05105-qt-study-nct07708272 Biopharma News en 2026-07-16T15:05:23.891Z Chia Tai Tianqing starts QT safety study for myelofibrosis drug TQ05105 https://www.appliedxl.com/news/suncadia-shr-a2009-solid-tumors-timing-nct05114759 Biopharma News en 2026-07-16T14:55:54.539Z Suzhou Suncadia pushes SHR-A2009 Phase 1 completion out three years to Dec 2026 https://www.appliedxl.com/news/suncadia-shr-a2009-solid-tumors-update-nct05114759 Biopharma News en 2026-07-16T14:55:25.622Z Suncadia's SHR-A2009 trial resumes reporting after status-registry gap https://www.appliedxl.com/news/mezzion-udenafil-2026-readout-nct03013751 Biopharma News en 2026-07-16T13:25:15.558Z Mezzion's udenafil cuts liver fibrosis marker in Fontan patients, not liver stiffness https://www.appliedxl.com/news/innocare-soficitinib-icp-332-2026-readout-nct07047612 Biopharma News en 2026-07-16T13:14:57.536Z InnoCare's soficitinib clears Phase II vitiligo endpoint versus placebo https://www.appliedxl.com/news/amt-b-v-elana-anastomotic-system-2026-readout-nct07005843 Biopharma News en 2026-07-16T12:54:48.378Z AMT Medical's sutureless bypass device hits 2.9% MACE at one year https://www.appliedxl.com/news/madrigal-resmetirom-2024-fda-decision-nct03900429 Biopharma News en 2026-07-16T12:25:45.761Z Madrigal's Rezdiffra won full FDA approval for MASH with fibrosis https://www.appliedxl.com/news/remix-rem-422-2026-data-nct06118086 Biopharma News en 2026-07-16T11:15:10.996Z Remix heads to AACR with a 43% ORR already in hand for REM-422 in ACC https://www.appliedxl.com/news/syntis-bio-synt-101-2026-readout-nct07307274 Biopharma News en 2026-07-16T11:16:39.343Z Syntis Bio's oral obesity pill shows early satiety-hormone signal in 32 healthy adults https://www.appliedxl.com/news/treprostinil-palmitil-inhalation-powder-tpip-pulmonary-nct05649748 Biopharma News en 2026-07-16T11:15:38.460Z Insmed's inhaled TPIP holds gains at 12 months, placebo group catches up https://www.appliedxl.com/news/merck-lipfendra-cholesterol-fda-approval-nct05952856 Biopharma News en 2026-07-16T12:00:42.646Z FDA approves Merck's oral PCSK9 inhibitor Lipfendra for high cholesterol https://www.appliedxl.com/news/disitamab-vedotin-bladder-cancer-pilot-data Biopharma News en 2026-07-16T19:44:42.382Z Small pilot links disitamab vedotin-toripalimab-radiotherapy to bladder preservation https://www.appliedxl.com/news/antioxidant-serum-uv-erythema-study Biopharma News en 2026-07-16T19:44:45.348Z Antioxidant serum cuts UV-induced erythema more than encapsulated vitamin C https://www.appliedxl.com/news/emicizumab-acquired-hemophilia Biopharma News en 2026-07-16T19:54:56.728Z Study reports short-term emicizumab use in acquired hemophilia A https://www.appliedxl.com/news/bms-admilparant-lung-fibrosis-biomarkers-nct04308681 Biopharma News en 2026-07-16T20:15:16.090Z Admilparant biomarker analysis maps how LPA1 blockade acts in lung fibrosis https://www.appliedxl.com/news/forward-fwd1802-pk-study-nct07476963 Biopharma News en 2026-07-16T14:55:06.264Z Forward Pharmaceuticals closes enrollment in FWD1802 food-effect PK study https://www.appliedxl.com/news/hengrui-shr-7367-solid-tumors-phase1-nct05740202 Biopharma News en 2026-07-16T15:05:12.559Z Hengrui completes Phase 1 SHR-7367 trial with enrollment cut to 22 from 182 https://www.appliedxl.com/news/lilly-mazdutide-alcohol-use-disorder-nct06817356 Biopharma News en 2026-07-16T15:25:45.015Z Lilly's mazdutide completes Phase 2 alcohol use disorder trial, data pending https://www.appliedxl.com/news/newsoara-hpp737-psoriasis-trial-nct07707141 Biopharma News en 2026-07-16T15:35:08.228Z Newsoara's HPP737 psoriasis trial surfaces in registry, results still unposted https://www.appliedxl.com/news/otsuka-jnt-517-pku-phase1-2-nct05781399 Biopharma News en 2026-07-16T15:25:15.332Z Otsuka's JNT-517 completes PKU Phase 1/2 study with enrollment reset to 163 https://www.appliedxl.com/news/egfr-tki-adjuvant-nsclc-meta-analysis Biopharma News en 2026-07-16T20:15:17.553Z Adjuvant EGFR-TKIs plus chemotherapy cut death risk in resected NSCLC meta-analysis https://www.appliedxl.com/news/ractigen-rag-17-sod1-als-phase1-nct05903690 Biopharma News en 2026-07-16T20:44:59.637Z RAG-17 shows safety and SOD1 knockdown in first-in-human ALS trial https://www.appliedxl.com/news/tirofiban-stroke-hemorrhage-readout Biopharma News en 2026-07-16T21:14:47.742Z RESCUE BT trial ties pre-EVT tirofiban to higher parenchymal hematoma risk in stroke https://www.appliedxl.com/news/sinovac-rabies-vaccine-phase3-readout Biopharma News en 2026-07-16T21:24:46.853Z Sinovac's serum-free rabies vaccine matches licensed shot on a simplified 4-dose schedule https://www.appliedxl.com/news/innovent-teprotumumab-thyroid-eye-disease-trial-design-nct07265258 Biopharma News en 2026-07-16T00:05:17.048Z Innovent designs first head-to-head trial of IGF-1R drug versus steroids in TED https://www.appliedxl.com/news/rso-021-pleural-effusion-phase-1-nct05278975 Biopharma News en 2026-07-16T00:05:21.116Z RSO-021 controlled malignant pleural effusion in 67% of patients at 12 weeks https://www.appliedxl.com/news/copd-type2-inflammation-meta-analysis Biopharma News en 2026-07-16T00:14:44.366Z Meta-analysis: T2-targeted biologics cut COPD exacerbations 23% across 7 trials https://www.appliedxl.com/news/maia-biotechnology-inc-thio-6-thio-dg-2023-readout-c7e4cf Biopharma News en 2026-07-16T16:52:20.391Z MAIA reports 90.5% disease control in heavily pretreated lung cancer cohort